Does lapatinib, a small-molecule tyrosine kinase inhibitor, constitute a breakthrough in the treatment of breast cancer?

Breast cancer (Tokyo, Japan)

Volumn 14, Issue 2, 2007, Pages 156-162

  Ito, Yoshinori ^a   Tokudome, Nahomi ^a   Sugihara, Tsutomu ^a   Takahashi, Shunji ^a   Hatake, Kiyohiko ^a  

^a CANCER CHEMOTHERAPY CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

BREAST TUMOR; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG COMBINATION; DRUG RESISTANCE; FEMALE; HUMAN; METABOLISM; REVIEW;

BREAST NEOPLASMS; CLINICAL TRIALS; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, ERBB-2;

EID: 34447286369     PISSN: 13406868     EISSN: None     Source Type: Journal    
DOI: 10.2325/jbcs.971     Document Type: Review

References (45)